Status:
COMPLETED
Contingent Incentives Plus Bupropion for Smoking in People With Schizophrenia
Lead Sponsor:
Brown University
Collaborating Sponsors:
National Institute on Drug Abuse (NIDA)
Conditions:
Schizophrenia and Disorders With Psychotic Features
Tobacco Use Disorder
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
There is a high prevalence of smoking among people with schizophrenia, and there are few smoking treatment programs for these smokers. The aims of this study are to investigate the separate and combin...
Detailed Description
There is a high prevalence of smoking among people with schizophrenia, and there are few smoking treatment programs for these smokers. In this study, we are investigating whether the combination of bu...
Eligibility Criteria
Inclusion
- Diagnosis of schizophrenia or schizoaffective disorder, smoke 20-50 cpd, clinically stable on antipsychotic and antidepressant medications
Exclusion
- Pregnant/nursing women, seizure disorder, lowered seizure threshold due to other medical conditions, positive urine drug screen positive breath alcohol test, past 2 weeks use of MAO inhibitors, any form of bupropion, cimetidine, phenobarbital, phenytoin, DA agonists, anorectics, stimulants
Key Trial Info
Start Date :
September 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2009
Estimated Enrollment :
57 Patients enrolled
Trial Details
Trial ID
NCT00136760
Start Date
September 1 2003
End Date
March 1 2009
Last Update
October 7 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Brown University
Providence, Rhode Island, United States, 02912